Rituximab therapy for Wegener's granulomatosis refractory to conventional treatment

Nefrologia. 2011;31(4):502-4. doi: 10.3265/Nefrologia.pre2011.May.10772.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / etiology*
  • Adult
  • Antibodies, Antineutrophil Cytoplasmic / blood
  • Antibodies, Antineutrophil Cytoplasmic / immunology
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Autoantigens / immunology
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Disease Susceptibility
  • Drug Resistance
  • Granulomatosis with Polyangiitis / complications
  • Granulomatosis with Polyangiitis / drug therapy*
  • Granulomatosis with Polyangiitis / immunology
  • Hemoptysis / etiology
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Diseases / etiology
  • Male
  • Methylprednisolone / therapeutic use
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Myeloblastin / immunology
  • Prednisone / therapeutic use
  • Rectal Neoplasms / etiology*
  • Recurrence
  • Rituximab

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Monoclonal, Murine-Derived
  • Autoantigens
  • Immunosuppressive Agents
  • Rituximab
  • Cyclophosphamide
  • Myeloblastin
  • Mycophenolic Acid
  • Prednisone
  • Methylprednisolone